Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors

Blood

Volumn 90, Issue 9, 1997, Pages 3546-3554

  Allay, James A ^b   Spencer, H Trent ^b   Wilkinson, Sarah L ^b   Belt, Judith A ^b   Blakley, Raymond L ^b   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIPYRIDAMOLE; DRAFLAZINE; HYPOXANTHINE; NITROBENZYLTHIOINOSINE; THYMIDINE; TRIMETREXATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; BONE MARROW TOXICITY; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTE; SENSITIZATION; SPLEEN;

EID: 0030783511     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.9.3546     Document Type: Article

References (46)

1. Pinedo HM, Zaharko DS, Bull J, Chabner BA: The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion, Cancer Res 37:445, 1977
2. Vogler WR, Mingioli ES, Garwood FA: The effect of methotrexate on granulocytic stem cells and granulopoiesis. Cancer Res 33:1628, 1973
3. Bogliolo GV, Lerza RA, Mencoboni MP, Saviane AG, Pannacciulli IM: Toxicity of trimetrexate on hemopoietic progenitor cells in normal mice. Anticancer Res 8:229, 1988
4. Pannacciulli I, Massa G, Bogliolo G, Ohio R, Sobrero A: Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells. Cancer Res 42:530, 1982
5. Stromhaug A, Slordal L, Warren DJ: Differential effects of the antifolates methotrexate, aminopterin and trimetrexate on murine haemopoietic progenitor cells. Br J Haematol 92:514, 1996
6. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ: Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol 23:461, 1995
7. Molineux G, Migdalska A, Haley J, Evans GS, Dexter TM: Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil. Blood 83:3491, 1994
8. Blau CA, Neff T, Papayannopoulou T: The hematologic effects of folate analogs: Implications for using the dihydrofolate reductase gene for in vivo selection. Human Gene Ther 7:2069, 1996
9. Howell SB, Mansfield SJ, Taetle R: Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate. Cancer Chemother Pharmacol 5:221, 1981
10. Howell SB, Mansfield SJ, Taetle R: Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res 41:945, 1981
11. Howell SB, Herbst K, Boss GR, Frei E: Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res 40:1824, 1980
12. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD, Baldwin SA: Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3:89, 1997
13. Cass CE: Nucleoside transport, in Georyopapadakou NH (ed): Drug Transport in Antimicrobial Therapy and Anticancer Therapy. New York, NY, Dekker, 1995, p 403
14. Baer HP, Serignese V, Moorji A, Van Belle H: In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters. Arch Pharmacol 343:365, 1991
15. Marina NM, Belt JA: Effect of nucleoside transport inhibitors on thymidine salvage and the toxicity of nucleoside analogs in mouse bone marrow granulocyte-macrophage progenitor cells. Cancer Commun 3:367, 1991
16. Willson JK, Fischer PH, Remick SC, Tutsch KD, Crem JL, Nieting L, Alberti D. Bruggink J, Trump DL: Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res 49:1866, 1989
17. Warnick CT, Muzik H, Paterson AR: Interference with nucleoside transport in mouse lymphoma cells proliferating in culture. Cancer Res 32:2017, 1972
18. Van Mouwerik TJ, Pangallo CA, Willson JK, Fischer PH: Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol 36:809, 1987
19. Grem JL, Fischer PH: Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 45:2967, 1985
20. Sorrentino BP: Drug Resistance Gene Therapy, in Brenner MK, Moen RC (eds): Gene Therapy in Cancer. New York, NY, Dekker, 1996, p 189
21. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP: A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87:2579, 1996
22. Lynch TP, Paran JH, Paterson AR: Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5′-monophosphate. Cancer Res 41:560, 1981
23. Whitney JB: Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine. Biochem Genet 16:667, 1978
24. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99, 1992
25. Randall TD, Weissman IL: Phenotypic and functional changes induced at the clunal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood 89:3596, 1997
26. Bodine DM, McDonagh KT, Seidel NE, Nienhuis AW: Survival and retro virus infection of murine hematopoietic stem cells in vitro: Effects of 5-FU and method of infection. Exp Hematol 19:206, 1991
27. Harrison DE, Lerner CP: Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood 78:1237, 1991
28. Weaver S, Haigwood NL, Hutchison CA, Edgell MH: DNA fragments of the Mus musculus beta globin haplotypes Hbbs and Hbbd. Proc Natl Acad Sci USA 76:1385, 1979
29. Pinedo HM, Zaharko DS, Bull JM, Chabner BA: The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 36:4418, 1976
30. Belt JA, Marina NM, Phelps DA, Crawford CR: Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 33:235, 1993
31. Hughes WL, Christine M, Stollar D: A radioimmunoassay for measurement of serum thymidine. Anal Biochem 55:468, 1973
32. Rongen GA, Smits P, Ver Donck K, Willemsen JJ, De Abreu RA, Van Belle H, Thien T: Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. J Clin Invest 95:658, 1995
33. Harrison DE: Competitive repopulation: A new assay for long-term stem cell functional capacity. Blood 55:77, 1980
34. Williams DA, Hsieh K, DeSilva A, Mulligan RC: Protection of hone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 166:210, 1987
35. Li MX, Banerjee D, Zhao SC, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR: Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83:3403, 1994
36. Schuetz JD, Wallace HJ, Diasio RB: 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 44:1358, 1984
37. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15:368, 1997
38. Cabral S, Leis S, Bover L, Nembrot M, Mordoh J: Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. Proc Natl Acad Sci USA 81:3200, 1984
39. Goel R, Howell SB: Modulation of the activity of cancer chemotherapeutic agents by dipyridamole. Cancer Treat Res 58:19, 1991
40. Fischer PH, Willson JK, Risueno C, Tutsch K, Bruggink J, Ranhosky A, Trump DL: Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. Cancer Res 48:5591, 1988
41. Harris LC, Marathi UK, Edwards CC, Houghton PJ, Srivastava DK, Vanin EF, Sorrentino BP, Brent TP: Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin Cancer Res 1:1359, 1995
42. Reese JS, Koc ON, Lee KM, Liu L, Allay JA, Phillips WP Jr, Gerson SL: Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6- benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc Natl Acad Sci USA 93:14088, 1996
43. Corey CA, DeSilva AD, Holland CA, Williams DA: Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75:337, 1990
44. Zhao SC, Li MX, Banerjee D, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR: Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther 1:27, 1994
45. Hawley RG, Lieu FH, Fong AZ, Hawley TS: Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1:136, 1994
46. Grez M, Akgun E, Hilberg F, Ostertag W: Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci USA 87:9202, 1990